9 completed, 2 terminated, 1 unknown. 12 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 9, Terminated 2, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Central Retinal Vein Occlusion: new trials by email Literature Review of Central Retinal Vein Occlusion trials Research Report on Central Retinal Vein Occlusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion Faricimab, Aflibercept, Sham Procedure - Macular Edema, Central Retinal Vein Occlusion | Phase 3 | Completed | Hoffmann-La Roche | 729 | 2021-03-02 | 2024-08-06 |
| Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection - Central Retinal Vein Occlusion | Phase 3 | Terminated | Novartis Pharmaceuticals | 493 | 2019-07-03 | 2023-01-30 |
| Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Conbercept Ophthalmic Injection, sham injection - Macular Edema, Central Retinal Vein Occlusion | Phase 3 | Completed | Chengdu Kanghong Biotech Co., Ltd. | 242 | 2016-05-24 | 2022-07-13 |
| Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) aflibercept, bevacizumab - Central Retinal Vein Occlusion | Phase 3 | Completed | The Emmes Company, LLC | 362 | 2014-09-01 | 2021-06-22 |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Sham injection, Ranibizumab 0.5 mg - Central Retinal Vein Occlusion | Phase 3 | Completed | Novartis Pharmaceuticals | 252 | 2013-11-12 | 2017-05-30 |
| Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Ranibizumab 0.5 mg/0.05 ml - Macular Edema, Central Retinal Vein Occlusion | Phase 3 | Completed | Novartis Pharmaceuticals | 357 | 2012-02-01 | 2016-10-27 |
| Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) Ranibizumab, Dexamethasone implant and sham injections - Visual Impairment, Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 243 | 2011-08-01 | 2016-09-27 |
| Bevacizumab for Central Retinal Vein Occlusion Study bevacizumab, Sham bevacizumab injection - Central Retinal Vein Occlusion | Phase 3 | Completed | Anders Kvanta | 60 | 2009-05-01 | 2011-11-22 |
| Atorvastatin for the Treatment of Retinal Vein Occlusion Atorvastatin, Placebo - Retinal Vein Occlusion, Retinal Vein Thrombosis | Phase 3 | Unknown | University of Toronto | 180 | 2007-08-01 | 2008-06-25 |
| A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO ranibizumab - Central Retinal Vein Occlusion, Macular Edema | Phase 3 | Completed | Aleris Helse | 32 | 2007-03-01 | 2012-01-19 |
| Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions nicotinic acid - Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion | Phase 2 / Phase 3 | Terminated | Palo Alto Medical Foundation | 36 | 2007-02-01 | 2019-11-13 |
| The ROVO Study: Radial Optic Neurotomy for CVO Intravitreal Triamcinolone, Radial Optic Neurotomy, Placebo - Sham Intravitreal Injection - Central Retinal Vein Occlusion | Phase 2 / Phase 3 | Completed | Rudolf Foundation Clinic | 2005-04-01 | 2009-10-30 |
Retinal Vein Occlusion (12) · Macular Edema (8) · Vision Disorders (4) · Neovascularization, Pathologic (1) · Thrombosis (1)
Cardiovascular Diseases (12) · Embolism and Thrombosis (12) · Eye Diseases (12) · Retinal Diseases (12) · Vascular Diseases (12) · Venous Thrombosis (12) · Thrombosis (11) · Macular Degeneration (8) · Retinal Degeneration (8) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Sensation Disorders (4) · Signs and Symptoms (4) · Metaplasia (1)
Ranibizumab (4) · aflibercept (3) · salicylhydroxamic acid (3) · Bevacizumab (2) · Atorvastatin (1) · Dexamethasone (1) · Niacin (1) · brolucizumab (1) · faricimab (1)
Novartis Pharmaceuticals (4) · Aleris Helse (1) · Anders Kvanta (1) · Chengdu Kanghong Biotech Co., Ltd. (1) · Hoffmann-La Roche (1) · Palo Alto Medical Foundation (1) · Rudolf Foundation Clinic (1) · The Emmes Company, LLC (1) · University of Toronto (1)
China (4) · Hungary (4) · United Kingdom (4) · United States (4) · Australia (3) · Austria (3) · Canada (3) · Czechia (3) · Germany (3) · Italy (3) · Poland (3) · Spain (3) · France (2) · Greece (2) · Hong Kong (2)
Anders Kvanta, MD, PhD (1) · Bettina Kinge, MD DMSc (1) · David Wong, MD (1) · Ingrid U Scott, M.D., M.P.H. (1) · Joel G Ray, MD MSc (1) · Michael Gaynon, MD (1) · Susanne Binder, M.D. (1)
PMID 20591399, PMID 22960949, PMID 28492910, PMID 31047340, PMID 31169862, PMID 31600368, PMID 33415354, PMID 34709363, PMID 34934034, PMID 35461831, PMID 36584835, PMID 37220815, PMID 37943541, PMID 38280653, PMID 40107501, PMID 42753135
2018 (1), U10EY023521 (1), U10EY023529 (1), U10EY023533 (1)